PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A to Z of Drugs : S

Records returned : 126 (on 19 Apr 2025 at 21:06:04).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
Sacrosidase
No Information Returned
02.05.05
Sacubitril/valsartan
Heart failure
Amber
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
SA
Important
Do not co-administer with an ACEi or ARB due to risk of angioedema.
02.05.05
Sacubitril/valsartan
Heart failure (children)
N/A
Formulations :
  • Granules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD2
02.05.05
Sacubitril/valsartan
Heart failure
Non Formulary
Formulations :
  • Granules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Do not co-administer with an ACEi or ARB due to risk of angioedema.
Only licensed for use in children.
04.09.01
Safinamide
Parkinson's disease
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
03.01.01
07.01.03
Salbutamol
Asthma
Green
Formulations :
  • Nebules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
03.01.01
07.01.03
Salbutamol
Respiratory disease indications
Green
Formulations :
  • Nebules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
03.01.01
07.01.03
Salbutamol
Asthma
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Unlicensed use in under 12 years of age.
03.01.01
07.01.03
Salbutamol
Delay of premature labour
Non Formulary
Formulations :
  • Infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
03.01.01
07.01.03
Salbutamol
Asthma
Non Formulary
Formulations :
  • Modified release tablets
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Salicylic acid
No Information Returned
Salmeterol
No Information Returned
05.03.01
Saquinavir mesylate
HIV infection
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
SA
NHSE
Important
Restricted Antimicrobial - requires GUM specialist approval
10.01.03
Sarilumab
Any paediatric use
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
10.01.03
Sarilumab
Rheumatoid arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Important
Severe disease only
06.01.02
Saxagliptin
Diabetes Mellitus
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Existing patients would not be expected to change therapy unless appropriate to do so.
06.01.02
Saxagliptin/dapagliflozin
Diabetes Mellitus
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Saxagliptin/metformin
No Information Returned
Sebelipase alfa
No Information Returned
Secnidazole
No Information Returned
Secobarbital sodium
No Information Returned
10.01.03
13.05.02
13.05.03
Secukinumab
Any paediatric use
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
10.01.03
13.05.02
13.05.03
Secukinumab
Hidradenitis suppurativa
Red
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
10.01.03
13.05.02
13.05.03
Secukinumab
Axial spondyloarthritis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
10.01.03
13.05.02
13.05.03
Secukinumab
Psoriatic arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
10.01.03
13.05.02
13.05.03
Secukinumab
Psoriasis
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
04.09.01
Selegiline hydrochloride
Parkinson's disease
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
04.09.01
Selegiline hydrochloride
Parkinson's disease (neuroprotective therapy)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Selenium
No Information Returned
Selenium sulfide
No Information Returned
06.01.02
Semaglutide
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Oral semaglutide is not a preferred route due to poor availability and gastrointestinal side effects. Use may be appropriate in a small cohort of patients where injection isn't suitable.
06.01.02
Semaglutide
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Dulaglutide is 1st line. Semaglutide is the 2nd line option for WEEKLY injection. Max of 13 Ozempic pens per patient per year (1 pen is a 4 week supply).
06.01.02
Semaglutide
Weight management in adults
Red
Formulations :
  • Pre-filled pen
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
R
NICE
06.01.02
Semaglutide
Prevention of cardiovascular events
N/A
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD2
06.01.02
Semaglutide
Weight management in adolescents
See narrative
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Only for the ASPH pilot clinics in young people aged 12 to 16 years.
06.01.02
Semaglutide (oral)
Diabetes Mellitus
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Oral semaglutide is not a preferred route due to poor availability and gastrointestinal side effects. Use may be appropriate in a small cohort of patients where injection isn't suitable.
06.01.02
Semaglutide (oral)
Diabetes Mellitus
N/A
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.02
Semaglutide (oral)
Diabetes Mellitus
See narrative
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
01.06.02
Senna
Constipation
Green
Formulations :
  • Liquid
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Sermorelin acetate
No Information Returned
Serrapeptase
No Information Returned
Sertindole
No Information Returned
Sertraline hydrochloride
No Information Returned
Sevelamer
No Information Returned
Sevoflurane
No Information Returned
Shingles (H/Z)
No Information Returned
Sibutramine
No Information Returned
Sildenafil
Raynaud's Phenomenon
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Transfer of prescribing to primary care only after specialist team initiation and supply of at least the first month of treatment.
Sildenafil
Penile rehabilitation
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
07.04.01
Sildenafil
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
07.04.05
Sildenafil (Erectile Dysfunction)
Erectile dysfunction
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Preferred
07.04.05
Sildenafil (Erectile Dysfunction)
Erectile dysfunction combination therapy
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Sildenafil (Female Sex Hormone)
No Information Returned
Sildenafil(Vasodilator Antihypertensive)
No Information Returned
Siltuximab
No Information Returned
Silver nitrate
No Information Returned
Silver sulfadiazine
No Information Returned
Simeprevir
No Information Returned
01.01.01
Simeticone
Colic
Green
Formulations :
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Children only
01.01.01
Simeticone
Endoscopic procedures
Red
Formulations :
  • Suspension
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
RSCH only - For the breakdown of bubbles to facilitate visualisation during endoscopic procedures.
Simple
No Information Returned
02.12.00
Simvastatin
Lipid modification
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Simvastatin and ezetimibe
No Information Returned
08.02.04
Siponimod
Multiple sclerosis
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NHSE
NICE
08.02.02
13.05.03
Sirolimus
Angiofibroma from tuberous sclerosis complex
Non Formulary
Formulations :
  • Gel
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD2
06.01.02
Sitagliptin
Diabetes Mellitus
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Preferred
Sitaxentan sodium
No Information Returned
Skin protectives,fillers and cleansers
No Information Returned
10.01.03
Sodium aurothiomalate
Rheumatoid arthritis
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Severe disease only
Sodium benzoate
No Information Returned
12.01.03
19.02.07
09.02.02
Sodium bicarbonate
Earwax removal
Green
Formulations :
  • Ear drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
5% ear drops. Available to purchase for self care.
12.01.03
19.02.07
09.02.02
Sodium bicarbonate
Metabolic acidosis
Red
Formulations :
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
https://www.toxbase.org/
https://www.toxbase.org/
12.01.03
19.02.07
09.02.02
Sodium bicarbonate
Salicylate poisoning, urine alkalisation
Red
Formulations :
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
https://www.toxbase.org/
https://www.toxbase.org/
12.01.03
19.02.07
09.02.02
Sodium bicarbonate
Reversal of QRS interval elongation following pois
Red
Formulations :
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
https://www.toxbase.org/
https://www.toxbase.org/
11.08.01
12.02.02
12.03.04
Sodium chloride
Corneal oedema
Green
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
5% eye drops for corneal oedema. Primary Care to prescribe by brand - OptimiseRx will be used to identify the most cost effective brand at the point of prescribing
11.08.01
12.02.02
12.03.04
Sodium chloride
Corneal oedema
Green
Formulations :
  • Eye drops (preservative free)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
5% preservative free eye drops for corneal oedema. Primary Care to prescribe by brand - OptimiseRx will be used to identify the most cost effective brand at the point of prescribing
11.08.01
12.02.02
12.03.04
Sodium chloride
Corneal oedema
Green
Formulations :
  • Eye ointment
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Primary Care to prescribe generically as 5% eye ointment preservative free (Alissa Healthcare) - to ensure licensed, Tariff product is supplied.
11.08.01
12.02.02
12.03.04
Sodium chloride
Nasal congestion
Green
Formulations :
  • Nasal drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
0.9 % sodium chloride nasal drops. Can be purchased for self care
11.08.01
12.02.02
12.03.04
Sodium chloride
Mobilisation of lower respiratory tract secretions
Blue
Formulations :
  • Inhalation
  • Nebules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
0.9% sodium chloride in 2.5ml unit dose ampoules. OptimiseRx will be used to inform Primary Care prescribers of the locally preferred, cost effective brand. Primary Care may prescribe on recommendation from the Respiratory Care Team who will ensure that patients have had suitable training and trial of equipment to ensure safe use.
11.08.01
12.02.02
12.03.04
Sodium chloride
Eye irrigation
Red
Formulations :
  • Irrigation solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
0.9% sodium chloride pods, sachets, bags, bottles
11.08.01
12.02.02
12.03.04
Sodium chloride
Eye irrigation
Red
Formulations :
  • Irrigation solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Balanced Salt Solution
11.08.01
12.02.02
12.03.04
Sodium chloride
Eye irrigation
Red
Formulations :
  • Irrigation solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Balanced Salt Solution Plus
11.08.01
12.02.02
12.03.04
Sodium chloride
Mobilisation of lower respiratory tract secretions
Red
Formulations :
  • Inhalation
  • Nebules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
3% hypertonic sodium chloride
11.08.01
12.02.02
12.03.04
Sodium chloride
Mobilisation of lower respiratory tract secretions
Red
Formulations :
  • Inhalation
  • Nebules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
6% hypertonic sodium chloride
11.08.01
12.02.02
12.03.04
Sodium chloride
Mobilisation of lower respiratory tract secretions
Red
Formulations :
  • Inhalation
  • Nebules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
7% hypertonic sodium chloride
01.01.01
11.08.02
Sodium citrate
Gastric acid neutralisation
Red
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prior to emergency caesarian section
01.06.04
Sodium citrate (Rectal)
Constipation
Green
Formulations :
  • Enema
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Sodium clodronate
No Information Returned
01.05.04
11.04.02
Sodium cromoglicate
Allergic conjunctivitis
Green
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Preferred
Sodium cromoglycate 2% or Antazoline with Xylometazoline (Otrivine-Antistin) are the preferred antihistamine/anti-inflammatory eye drops
01.05.04
11.04.02
Sodium cromoglicate
Food allergy
Blue
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
GP initiation on specialist recommendation.
Sodium dihydrogen phosphate dihydrate
No Information Returned
Sodium feredetate
No Information Returned
Sodium fluoride
No Information Returned
05.01.07
Sodium fusidate
Bacterial infection
Red
Formulations :
  • Infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Sodium glycerophosphate
No Information Returned
Sodium hyaluronate
Dry eyes
Green
Formulations :
  • Eye drops
  • Eye drops (preservative free)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Moderate dry eye. Prescribe by brand (primary care)
1st line: Eyeaze preservative free (0.1%, 0.2%, 0.4%) VIZhyal preservative free (0.1%, 0.2%, 0.4%) 2nd line: Hy-Opti 0.2% Clinitas Multi preservative free (0.2%, 0.4%)
11.08.03
Sodium hyaluronate
Ocular surgery
Red
Formulations :
  • Intra-ocular injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Sodium hypochlorite
No Information Returned
Sodium lactate
No Information Returned
04.01.01
Sodium oxybate
Narcolepsy
Red
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
Important
Narcolepsy in adults - specialist use only.
04.01.01
Sodium oxybate
Narcolepsy
Red
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
Un
NHSE
Important
Narcolepsy in children - specialist centres only
Sodium phenylbutyrate
No Information Returned
01.06.02
01.06.05
Sodium picosulfate
Constipation
Green
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
01.06.02
01.06.05
Sodium picosulfate
Faecal impaction (adults)
Red
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Off-label for faecal impaction
01.06.02
01.06.05
Sodium picosulfate
Faecal impaction (children)
Red
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Off-label for faecal impaction
01.06.02
01.06.05
Sodium picosulfate
Pre-operative bowel cleansing (adults)
Red
Formulations :
  • Sachets (powder)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Picolax sachets. SASH / RSFT = Plenvu (polyethylene glycol) is 1st line. ASPH = paediatrics only
01.06.02
01.06.05
Sodium picosulfate
Pre-operative bowel cleansing (children)
Red
Formulations :
  • Sachets (powder)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Picolax sachets. Licensed in >1 year of age.
01.06.02
01.06.05
Sodium picosulfate
Pre-operative bowel cleansing (adults)
Red
Formulations :
  • Sachets (powder)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Citrafleet sachets. RSFT 2nd line if Picolax is unsuitable / unavailable.
01.06.02
01.06.05
Sodium picosulfate
Faecal impaction (adults)
Red
Formulations :
  • Sachets (powder)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Off-label for faecal impaction
Picolax sachets.
01.06.02
01.06.05
Sodium picosulfate
Faecal impaction (children)
Red
Formulations :
  • Sachets (powder)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Off-label for faecal impaction
ASPH: 2nd line after macrogol. RSFT: If Movicol/Laxido disimpaction regimen has been unsuccessful (with/without a stimulant laxative).
01.06.02
01.06.05
Sodium picosulfate
Faecal impaction (adults)
Red
Formulations :
  • Sachets (powder)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Off-label for faecal impaction
Citrafleet sachets. Off-label use.
01.06.02
01.06.05
Sodium picosulfate
Constipation
Red
Formulations :
  • Sachets (powder)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Important
PICOLAX sachets - off-label use. ADULTS only at SASH. Adults and children at RSFT.
01.06.02
01.06.05
Sodium picosulfate
Constipation
Red
Formulations :
  • Sachets (powder)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Important
CITRAFLEET - ADULTS only. Off-label use
Sodium polystyrene sulfonate
No Information Returned
Sodium stibogluconate
No Information Returned
02.13.00
Sodium tetradecyl sulphate
Varicose veins
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
13.10.02
19.02.07
Sodium thiosulfate
Cyanide poisoning
Red
Formulations :
  • Intravenous injection (IV)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
https://www.toxbase.org/
https://www.toxbase.org/
Sodium valproate
No Information Returned
04.08.01
Sodium valproate (NON childbearing potential)
Epilepsy
Blue
Formulations :
  • Gastro-resistant tablets
  • Modified release tablets
  • Oral solution
  • Tablets
  • Crushable tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.08.01
Sodium valproate (NON childbearing potential)
Epilepsy
Blue
Formulations :
  • Capsules (slow release)
  • Granules (slow release)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Sodium valproate (NON childbearing potential)
Mental Health disorders
Blue
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.08.01
Sodium valproate (NON childbearing potential)
Epilepsy
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Sodium valproate (with childbearing potential)
Mental Health disorders
Amber
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.08.01
Sodium valproate (with childbearing potential)
Epilepsy
Amber
Formulations :
  • Gastro-resistant tablets
  • Modified release tablets
  • Oral solution
  • Tablets
  • Crushable tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Important
Pregnancy Prevention Programme required. See MHRA advice
04.08.01
Sodium valproate (with childbearing potential)
Epilepsy
Amber
Formulations :
  • Capsules (slow release)
  • Granules (slow release)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Important
Pregnancy Prevention Programme required. See MHRA advice
04.08.01
Sodium valproate (with childbearing potential)
Epilepsy
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Important
Pregnancy Prevention Programme required. See MHRA advice
Sodium zirconium cyclosilicate
No Information Returned
05.03.03
Sofosbuvir
Hepatitis C
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
SA
NHSE
NICE
Important
Requires approval from HCV national team for use
Sofosbuvir/velpatasvir
No Information Returned
05.03.03
Sofosbuvir/velpatasvir/voxilaprevir
Hepatitis C
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Soft soap
No Information Returned
07.04.02
Solifenacin
Overactive bladder (adults)
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
1st line unless contra-indicated
07.04.02
Solifenacin
Overactive bladder (adults)
Green (see narrative)
Formulations :
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
Only for patients with swallowing difficulties. Prescribe as solifenacin 1mg/ml oral SUSPENSION
07.04.02
Solifenacin
Overactive bladder (adults)
Non Formulary
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Important
Prescribe as solifenacin 1mg/ml oral SUSPENSION
Solifenacin/tamsulosin
No Information Returned
06.01.01
Soluble insulin - Hypurin porcine neutral
(Insulin)
Diabetes Mellitus
Blue
Formulations :
  • Cartridges
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Initiation by diabetes team only
06.01.01
Soluble insulin - Actrapid
(Insulin)
Diabetes Mellitus
Green
Formulations :
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.01
Soluble insulin - Humulin R
(Insulin)
Diabetes Mellitus
Non Formulary
Formulations :
  • Pre-filled pen
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
06.01.01
Soluble insulin - Humulin S
(Insulin)
Diabetes Mellitus
Green
Formulations :
  • Cartridges
  • Vials
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Prescribe by brand and state form.
Soluble insulin (Neutral insulin)
No Information Returned
Solvent ether
No Information Returned
Somatorelin
No Information Returned
06.05.01
Somatropin
Growth failure - children
Amber
Formulations :
  • Intra-articular injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
Sorafenib
No Information Returned
02.04.00
Sotalol hydrochloride
Arrhythmias
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
02.02.03
13.05.03
Spironolactone
Heart failure
Green
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Spironolactone is the preferred aldosterone antagonist for all stages of heart failure.
02.02.03
13.05.03
Spironolactone
Oedema
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
02.02.03
13.05.03
Spironolactone
Hypertension
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Step 4 of the hypertension pathway. Adjunct in resistant hypertension
02.02.03
13.05.03
Spironolactone
Alopecia
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
Important
FEMALES ONLY - option for non-scarring alopecia
Spironolactone with loop diuretics
No Information Returned
Spironolactone with thiazides
No Information Returned
Squill
No Information Returned
Squill opiate
No Information Returned
Squill/ipecacuanha
No Information Returned
Stannous fluoride
No Information Returned
Stanozolol
No Information Returned
05.03.01
Stavudine
HIV infection
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
NHSE
Important
Restricted Antimicrobial - requires GUM Specialist approval
Ster larvae
No Information Returned
01.04.01
01.06.01
Sterculia
Constipation
Green
Formulations :
  • Sachets (granules)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Sterile water
No Information Returned
04.08.01
Stiripentol
Epilepsy
Red
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Initiation and adjustment by consultant paediatricians only.
12.03.03
Strepsils
Symptomatic relief of sore throat / mouth
Non Formulary
Formulations :
  • Lozenges
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
02.10.02
Streptokinase
Thrombolysis
Red
Formulations :
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
02.10.02
Streptokinase
Pleural effusion
Red
Formulations :
  • Intrapleural injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Streptokinase and streptodornase
No Information Returned
05.01.04
05.01.09
Streptomycin
Bacterial infection
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
SA
Important
Restricted Antimicrobial - requires Microbiology Specialist Approval.
06.06.02
Strontium ranelate
Osteoporosis
Red
Formulations :
  • Sachets (granules)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
U
01.03.03
01.07.01
Sucralfate
Gastro protection
Red
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
Sucrase
No Information Returned
Sucroferric oxyhydroxide
No Information Returned
Sucrose
No Information Returned
Sulconazole nitrate
No Information Returned
05.01.08
Sulfadiazine
Bacterial infection
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Toxoplasmosis only
Sulfamethoxypyridazine
No Information Returned
Sulfapyridine
No Information Returned
01.05.01
10.01.03
Sulfasalazine
Inflammatory bowel disease
Amber
Formulations :
  • Gastro-resistant tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
Enteric coated tablets are significantly more expensive. Reserve for patients unable to tolerate plain tablets.
01.05.01
10.01.03
Sulfasalazine
Inflammatory bowel disease
Amber
Formulations :
  • Suppositories
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
01.05.01
10.01.03
Sulfasalazine
Rheumatology indications
Amber
Formulations :
  • Gastro-resistant tablets
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
01.05.01
10.01.03
Sulfasalazine
Inflammatory bowel disease
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Sulfinpyrazone
No Information Returned
Sulfur
No Information Returned
Sulindac
No Information Returned
06.01.01
Suliqua (Insulin glargine/lixisenatide)
Diabetes Mellitus
Non Formulary
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Sulpiride
No Information Returned
Sultiame
No Information Returned
04.07.04
Sumatriptan
Migraine (acute)
Green
Formulations :
  • Injection
  • Nasal spray
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Preferred
Prescribe generically.
04.07.04
Sumatriptan
Cluster headaches
Green
Formulations :
  • Injection
  • Nasal spray
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe generically.
Sumatriptan succinate
No Information Returned
Sunitinib
No Information Returned
Suxamethonium chloride
No Information Returned
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More